Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases - Quiz - MDSpire

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

  • By

  • Armelle Otiniano

  • Zoe van de Wyngaert

  • Eolia Brissot

  • Rémy Dulery

  • Joel Gozlan

  • Anne Daguenel

  • Yasmine Abi Aad

  • Laure Ricard

  • Nicolas Stocker

  • Anne Banet

  • Agnes Bonnin

  • Tamim Alsuliman

  • Zora Marjanovic

  • Aurélie Schnuriger

  • Paul Coppo

  • Ollivier Legrand

  • Karine Lacombe

  • Mohamad Mohty

  • Florent Malard

  • December 8, 2022

  • 0 min

Share

Original Source(s)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

  • by Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Rémy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet, Agnes Bonnin, Tamim Alsuliman, Zora Marjanovic, Aurélie Schnuriger, Paul Coppo, Ollivier Legrand, Karine Lacombe, Mohamad Mohty, Florent Malard

  • December 8, 2022

Related Content

Utilizing AI-Enhanced Chest X-Rays and Hematological Indicators to Forecast Mortality and Intubation in COVID-19 Patients at a Secondary Referral Hospital in Indonesia

Normalization of Seasonality and Age Distribution of Pediatric RSV Infection Following the Pandemic Disruption in the Netherlands

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib